Generali Investments CEE investicni spolecnost a.s. Buys New Stake in iShares Biotechnology ETF (NASDAQ:IBB)

Generali Investments CEE investicni spolecnost a.s. purchased a new position in iShares Biotechnology ETF (NASDAQ:IBB) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 86,000 shares of the financial services provider’s stock, valued at approximately $11,370,000. iShares Biotechnology ETF makes up about 1.2% of Generali Investments CEE investicni spolecnost a.s.’s portfolio, making the stock its 10th biggest holding. Generali Investments CEE investicni spolecnost a.s. owned approximately 0.18% of iShares Biotechnology ETF at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its holdings in shares of iShares Biotechnology ETF by 29.3% during the third quarter. BNP Paribas Financial Markets now owns 2,380,229 shares of the financial services provider’s stock worth $346,561,000 after buying an additional 538,899 shares in the last quarter. Commerce Bank grew its holdings in shares of iShares Biotechnology ETF by 1.8% during the third quarter. Commerce Bank now owns 743,366 shares of the financial services provider’s stock worth $108,234,000 after buying an additional 12,921 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its holdings in shares of iShares Biotechnology ETF by 32.9% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 663,000 shares of the financial services provider’s stock worth $96,533,000 after buying an additional 164,000 shares in the last quarter. Main Management ETF Advisors LLC grew its holdings in shares of iShares Biotechnology ETF by 2.5% during the third quarter. Main Management ETF Advisors LLC now owns 593,370 shares of the financial services provider’s stock worth $86,395,000 after buying an additional 14,535 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of iShares Biotechnology ETF during the fourth quarter worth $55,010,000. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Up 0.5 %

iShares Biotechnology ETF stock opened at $136.95 on Friday. The company has a fifty day simple moving average of $136.01 and a 200-day simple moving average of $140.40. The firm has a market capitalization of $6.47 billion, a price-to-earnings ratio of 24.52 and a beta of 0.84. iShares Biotechnology ETF has a 52-week low of $123.60 and a 52-week high of $150.57.

iShares Biotechnology ETF Cuts Dividend

The company also recently declared a dividend, which was paid on Friday, December 20th. Stockholders of record on Tuesday, December 17th were given a dividend of $0.0624 per share. The ex-dividend date was Tuesday, December 17th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.